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Summary
 
Susceptibility to Fas-mediated apoptosis in nontolerant B cells is regulated in a receptor-specific
fashion. To explore the regulation of Fas killing in tolerant, autoreactive B cells, mice doubly
transgenic for hen egg lysozyme (HEL)–specific B cell receptors and soluble HEL were exam-
ined. Engagement of CD40 led to enhanced Fas expression and acquisition of sensitivity to
Fas-mediated apoptosis in tolerant B cells, similar to that observed in nontolerant, receptor
transgenic B cells. Engagement of surface immunoglobulin by specific (HEL) antigen failed to
induce Fas resistance in tolerant B cells, in contrast to its effect on nontolerant B cells; how-
ever, cross-linking of biotinylated HEL with streptavidin induced similar levels of Fas resistance
in tolerant and nontolerant B cells, which approximated the degree of Fas resistance produced
by anti-Ig. Unlike surface Ig (sIg) engagement, physiological engagement of IL-4 receptors
produced similar levels of Fas resistance in tolerant and nontolerant B cells. Thus, tolerant B
cells differ from nontolerant B cells in the diminished capacity of surface immunoglobulin en-
gagement to produce Fas resistance; however, tolerant B cells can be induced to become resis-
tant to Fas-mediated apoptosis by IL-4 or by higher order cross-linking of sIg receptors.
 
B
 
cells can be targets for cytotoxicity mediated by CD4
 
1
 
Th1 effector cells that express Fas ligand and induce
apoptosis in a Fas (CD95)-dependent fashion (1–7). Sus-
ceptibility to Fas-mediated apoptosis is dependent on the
state of B cell activation and is regulated in a receptor-spe-
cific fashion. CD40 engagement by soluble, chimeric CD40
ligand (CD40L)
 
1
 
 induces expression of cell surface Fas and
renders primary B cells highly sensitive to Fas killing (8–10).
In contrast, antigen receptor cross-linking actively opposes
Th1 cell–mediated cytotoxicity (Th1-CMC), as shown by
the observation that B cells treated with CD40L in conjunc-
tion with anti-IgM, or in conjunction with specific antigen,
are resistant to Th1-CMC (8, 11, 12). In addition to anti-
gen receptor engagement, B cells are also rendered Fas-
resistant by IL-4 receptor engagement (13). Both anti-IgM
and IL-4 induce protection against Fas killing that is not as-
sociated with a loss or alteration of Fas expression, and that
is intrinsic to the B cell target itself (11, 13). Despite these
similarities, the signaling pathways engaged by anti-IgM
and IL-4 to produce Fas resistance are distinct as shown by
several criteria, and suboptimal doses of these reagents act
in synergy to bring about maximal levels of Fas resistance
(11, 13, 14).
Autoreactive B cells express receptors with specificity for
self-antigen, and several mechanisms provide for their ex-
clusion from the immune repertoire. High affinity autore-
active B cells undergo clonal deletion or receptor editing in
the bone marrow (15–18). Many of the remaining clones
that recognize autoantigens migrate to the periphery where
they exist in a state of tolerance characterized by impaired
signaling via the antigen receptor, normal signaling via
CD40 and IL-4R, and shortened life span (19–21). Several
lines of evidence suggest that Fas (CD95) plays a role in
regulating the disposition of activated, tolerant, autoreac-
tive B cells: (
 
a
 
) Fas-deficient 
 
lpr/lpr
 
 mice and Fas knockout
mice express excessively high titers of autoantibodies (22,
23); (
 
b
 
) the recovery of tolerant B cells after adoptive trans-
fer is improved if the B cells are Fas-deficient or if the
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; CD40L,
soluble, chimeric CD40 ligand; DTg, double transgenic (anti-HEL/
HEL); HEL, hen egg lysozyme; rIL-4, recombinant mouse interleukin 4;
sHEL, soluble hen egg lysozyme; sIg, surface Ig; STg, single transgenic
(anti-HEL); Th1-CMC, Th1 cell-mediated cytotoxicity.
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cotransferred T cells are deficient in Fas ligand (24, 25); and
(
 
c
 
) transgenic mice that overexpress IL-4 produce autoanti-
bodies (13).
To determine the potential role of inducible Fas resis-
tance in determining the fate of tolerant B cells, we carried
out experiments using anti–hen egg lysozyme (HEL)/HEL
double transgenic (DTg) mice. We sought to determine
whether the rules for receptor-specific induction of Fas re-
sistance that we previously identified in nontolerant B cells
would apply to tolerant B cells as well. This is particularly
relevant with respect to the antigen receptor, where it is
important to delineate the capacity of self-antigen to pro-
tect autoreactive B cells against Fas-mediated apoptosis.
 
Materials and Methods
 
Animals. 
 
Male BALB/cByJ and C57BL/6J mice at 8–14 wk
of age were obtained from The Jackson Laboratory (Bar Harbor,
ME). MD4 
 
3 
 
ML5 anti-HEL/soluble HEL (sHEL) DTg and
MD4 anti-HEL single transgenic (STg) breeders were kindly pro-
vided by Dr. Michael C. Carroll (Harvard Medical School, Bos-
ton, MA) and Dr. Christopher C. Goodnow (Howard Hughes
Medical Institute and Stanford University School of Medicine,
Stanford, CA). DTg and STg mice were bred at Boston Univer-
sity Medical Center and offspring were screened as described be-
low. DTg and STg mice were studied at 8–14 wk of age.
 
Genotyping.
 
The mice were genotyped by PCR carried out
on tail-digest DNA (26). In brief, tail DNA was analyzed by two
separate PCR reactions. The first reaction, to screen for the pres-
ence of endogenous B cell antigen receptor (BCR) and anti-HEL
transgenic BCR, included three oligonucleotide primers: Ig
 
R1 
 
5
 
9
 
ACCACAGACCAGCAGGCAGA 3
 
9
 
, shared by both the en-
dogenous and transgenic BCR; Ig
 
F1
 
 5
 
9
 
 GCGACTCCATCAC-
CAGCGAT 3
 
9
 
, unique to the endogenous BCR; and Ig
 
F2
 
 5
 
9
 
CTGGAGCCCTAGCCAAGGAT 3
 
9
 
, unique to the transgenic
BCR. The second PCR reaction used an oligonucleotide primer
pair to screen for the presence of sHEL: HEL
 
F1
 
 5
 
9
 
 GAGCGT-
GAACTGCGCGAAGA 3
 
9
 
, and HEL
 
R1
 
 5
 
9
 
 TCGGTACCCT-
TGCAGCGGTT 3
 
9
 
. After 32 cycles of amplification, the PCR
products were size fractionated on 8% native polyacrylamide gels
and visualized by ultraviolet transillumination after ethidium bro-
mide staining. DTg anti-HEL/sHEL mice yield PCR products of
264 bp (endogenous Ig), 430 bp (Ig transgene), and 160 bp
(lysozyme transgene).
 
B Cell Purification. 
 
Splenic B cells were purified by depletion
of T cells with antibody (13-4 anti-Thy 1.2, GK1.5 anti-CD4,
and 3.1.55 anti-CD8), plus rabbit complement, and dead cells
were removed by sedimentation on Lympholyte M (Cedarlane
Labs., Ltd., Hornby, Ontario, Canada), as previously described
(8). Viable cells were resuspended in RPMI 1640 medium (Bio-
Whittaker, Walkersville, MD) supplemented with 5% heat-inac-
tivated FCS (Sigma Chemical Co., St. Louis, MO), 50 
 
m
 
M 2-mE,
2 mM l-glutamine, 10 mM Hepes, pH 7.2, 100 U/ml penicillin,
and 100 
 
m
 
g/ml streptomycin.
 
Cell-mediated Cytotoxicity.
 
B cells (2 
 
3
 
 10
 
6
 
) were cultured in
1.2 ml of supplemented RPMI 1640 in the wells of 24-well tissue
culture plates (Costar Corp., Cambridge, MA) for a total of 16 h
at 37
 
8
 
C and 6% CO
 
2
 
. B cells were stimulated with CD40L–
CD8
 
a
 
 fusion protein (CD40L) cross-linked with CD8-specific
antibody (as 1:10 and 1:80 dilutions of dialyzed supernatant, re-
spectively) to induce susceptibility to Fas-mediated apoptosis, as
previously described, or with CD40L–CD8
 
a
 
/anti-CD8 in com-
bination with sHEL, F(ab
 
9
 
)
 
2
 
 fragments of goat anti–mouse IgM
antibody (anti-IgM), dextran-conjugated anti–mouse IgD anti-
body (anti-IgD), or recombinant mouse IL-4 (rIL-4). B cells
were also treated with CD40L–CD8
 
a
 
/anti-CD8 in combination
with biotinylated sHEL in the presence or absence of streptavidin
(SA). B cells were then tested as targets for Fas-mediated apopto-
sis in standard lectin-dependent 4-h 
 
51
 
Cr–release assays, as previ-
ously described (11), using AE7 CD4
 
1
 
 Th1 effector cells.
 
Flow Cytometric Analysis.
 
B cells stimulated as described above
were examined for Fas expression by staining with PE-conju-
gated Jo-2 anti-Fas Ab or anti-CD28 isotype-matched control Ab
(PharMingen, San Diego, CA) as previously described (11, 13).
Unstimulated DTg and STg B cells were examined for bound
HEL by staining with biotin-conjugated HyHEL9 anti-HEL
monoclonal antibody, followed by PE-conjugated SA secondary
antibody (PharMingen). B cells were stained with HyHEL9 in
the presence of 0.1% azide before and after incubation with sHEL
(Sigma Chemical Co.) at 100 ng/ml for 1 h at 4
 
8
 
C. Cells were
then washed and analyzed by flow cytometry on a FACScan
 
Ò
 
 in-
strument (Becton-Dickinson, San Jose, CA).
 
Reagents.
 
Supernatant from transfected J588L cells that se-
crete a chimeric CD40L–CD8
 
a 
 
fusion protein (27) was collected
and dialyzed against 25,000 mol wt cutoff dialysis tubing, as pre-
viously described (28). A similarly dialyzed supernatant contain-
ing anti-CD8 antibody from the 53-6-72 hybridoma was used to
cross-link the fusion protein. rIL-4 was obtained from Genzyme
Corp. (Cambridge, MA). F(ab
 
9
 
)
 
2
 
 fragments of affinity purified
goat anti–mouse IgM were obtained from Jackson Immunore-
search Labs. (West Grove, PA). Mitogenic monoclonal anti-IgD
(H
 
d
 
a
 
/1) conjugated to dextran was provided by Dr. James J.
Mond (Uniformed Health Services University, Bethesda, MD;
reference 29). [
 
51
 
Cr]sodium chromate (0.5 mCi/mmol) was ob-
tained from Dupont-NEN (Boston, MA). sHEL was obtained
from Sigma Chemical Co. Biotin-conjugated HyHEL9 (anti-
HEL) was provided by Dr. Goodnow. SA was obtained from
PharMingen.
 
Results
 
Several previous reports suggest that Fas-mediated apop-
tosis may play a role in regulating autoreactive B cells, in
which case inducible Fas resistance might be expected to
influence this process (13, 22–25). To directly study the ca-
pacity of tolerant B cells to acquire resistance to Fas-medi-
ated apoptosis in a receptor-specific fashion, mice express-
ing transgenes for B cell receptors that recognize HEL
(anti-HEL), with or without transgenes for sHEL, were ex-
amined. B cells from DTg mice develop in the continual
presence of soluble autoantigen and are rendered tolerant.
B cells from STg mice are not exposed to cognate antigen
during development and thus are not tolerized (30, 31).
Primary B cells from DTg and STg mice were stimulated
for 16 h with CD40L to assess relative levels of Fas sensitiv-
ity. As shown in Fig. 1
 
 A
 
, CD40L treatment resulted in
substantial upregulation of Fas expression, which was simi-
lar for B cells from DTg and STg mice. B cells were then
tested as targets for Fas-mediated apoptosis in lectin-depen-
dent 4-h 
 
51
 
Cr–release assays using FasL-bearing AE7 CD4
 
1
 
Th1 effector cells, as previously described (11). As shown
in Fig. 1 
 
B
 
, CD40L-stimulated B cells from both DTg and 
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STg mice were susceptible to Th1-CMC at a level that ap-
proximated the specific lysis of CD40L-stimulated wild-
type C57BL/6J B cells. In 10 separate experiments, the
specific lysis of DTg B cells was 39.1 
 
6 
 
3.9% (mean 
 
6
 
SEM) and the specific lysis of STg B cells was 43.9 
 
6
 
 3.4%,
indicating little difference between the two populations.
To examine the capacity of surface Ig (sIg) to mediate Fas
resistance in tolerant B cells, cytotoxicity assays were car-
ried out following concurrent treatment of B cell targets with
CD40L plus sHEL for 16 h. As shown in Fig. 1 
 
B
 
, the ad-
dition of sHEL to nontolerant B cells from STg mice express-
ing lysozyme-specific BCR produced virtually complete
resistance to Th1-CMC (and this could not be attributed to
a change in the level of Fas expression; compare with Fig. 1
 
A
 
). In direct contrast, sHEL completely failed to modulate
the Fas sensitivity of CD40L-stimulated tolerant B cells
from DTg mice. Similar results were obtained using soluble
recombinant FasL (provided by Dr. Andreas Hohlbaum,
Boston University School of Medicine) to effect cytolysis
(data not shown). HEL had no effect on the Fas sensitivity
of wild-type B cells, in keeping with the expectation that
normal mice would have no or few B cells with chicken
lysozyme specificity. Thus, engagement of sIg by specific
antigen did not alter the susceptibility to Fas-mediated apop-
tosis of tolerant B cells, yet induced a high level of Fas re-
sistance in nontolerant, HEL-specific B cells.
Cytotoxicity assays were also carried out to examine the
effect of cross-linking B cell receptors with anti-Ig. Primary
B cells from wild-type, STg, and DTg mice were treated
with CD40L alone or were treated with the combination
Figure 1. Fas expression, Fas sensitivity, and Fas resistance are induced
in tolerant B cells by specific receptor engagement. (A) Primary B cells
from STg or DTg mice were cultured in medium alone (medium) or were
stimulated with either CD40L–CD8a fusion protein cross-linked with
CD8-specific antibody (CD40L), CD40L plus soluble HEL at 100 ng/ml
(CD40L1sHEL), or CD40L plus recombinant IL-4 at 100 U/ml
(CD40L1IL-4) for 16 h as indicated. B cells were stained with PE-conju-
gated Jo-2 anti-Fas antibody (filled tracing), or with PE-conjugated anti-
CD28 antibody, an isotype-matched control antibody (open tracing), in the
presence of 2% rabbit serum. Stained cells were analyzed by flow cytome-
try; relative cell number is shown as a function of fluorescence intensity in
arbitrary units. One of three comparable experiments is shown. (B) Pri-
mary B cells from wild-type (WT, C57BL/6J), STg, or DTg mice were
stimulated with either CD40L–CD8a fusion protein cross-linked with
CD8-specific antibody (black bars), or CD40L plus sHEL at 100 ng/ml
(hatched bars), for 16 h as indicated. B cells were then radiolabeled and
tested for susceptibility to Fas-dependent lysis in standard 4-h lectin-
dependent 51Cr–release assays using AE7 CD41 Th1 effector cells. Re-
sults for E/T cell ratios of 9:1 are presented. For each condition, the mean
percentage of specific lysis of triplicate assays is displayed, along with a line
indicating the SEM. One of three comparable experiments is shown.
Figure 2. Antigen receptor cross-linking induces Fas resistance in tol-
erant B cells. (A) Primary B cells from wild-type (WT, C57BL/6J), STg,
or DTg mice were stimulated with either CD40L–CD8a fusion protein
cross-linked with CD8-specific antibody (black bars), or CD40L plus
F(ab9)2 fragments of goat anti–mouse IgM at 10 mg/ml (hatched bars), for
16 h as indicated. B cells were then radiolabeled and tested for susceptibil-
ity to Fas-dependent lysis in standard 4-h lectin-dependent 51Cr–release
assays using AE7 CD41 Th1 effector cells. Results for E/T cell ratios of 9:1
are presented. For each condition, the mean percentage of specific lysis of
triplicate assays is displayed, along with a line indicating the SEM. One of
three comparable experiments is shown. (B) Primary B cells from STg or
DTg mice were stimulated with either CD40L (black bars) or CD40L plus
anti-IgD at 100 ng/ml (hatched bars) for 16 h as indicated. B cells were
then radiolabeled and tested for susceptibility to Fas-dependent lysis as
above. Results for E/T cell ratios of 9:1 are presented as described above. 
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of CD40L plus anti-IgM for 16 h. As shown in Fig. 2 
 
A
 
,
the addition of anti-IgM to CD40L produced similar levels
of resistance to Th1-CMC in all three B cell populations.
Further, STg and Dtg B cell populations differed little in
the levels of Fas resistance produced by anti-IgD (Fig. 2 
 
B
 
).
Thus, although sIg engagement by specific antigen failed to
induce Fas resistance in tolerant B cells, sIg cross-linking by
either anti-IgM or anti-IgD did so. These results indicate
that the variant effect of sHEL on tolerant and nontolerant
B cells cannot be explained by the different levels of sIgM
and sIgD expressed.
In the anti-HEL/sHEL system, tolerant B cells develop
in the presence of specific antigen, raising the possibility
that constitutive occupation of transgenic BCR by HEL
might block additional antigen binding (31). To address
this issue, the degree of BCR occupancy was evaluated by
flow cytometric analysis after staining of B cells with
HyHEL9. DTg and STg B cells were examined before and
after addition of sHEL in vitro. As shown in Fig. 3, addi-
tion of HEL to the STg BCR produced a marked increase
in HEL binding detected by HyHEL9. Addition of HEL to
the DTg BCR also produced an increase in HEL binding
although the increment was not as great as that observed
with STg B cells, because DTg B cells contain some bound
HEL at baseline, derived from endogenous sources. Thus,
DTg BCR can be effectively engaged by added sHEL, al-
beit to a lesser extent than the STg BCR. The identifica-
tion of unoccupied receptors in DTg B cells suggests that
some mechanism other than simple receptor blockade is re-
sponsible for deficiencies in sIg signaling unless there is an
incremental threshold required for induction of Fas-resis-
tance.
The disparity between sHEL and anti-Ig in the induc-
tion of Fas resistance in tolerant B cells could relate to the
relative degree of sIg cross-linking produced by these agents.
To address this possibility, the outcome of cross-linking
sHEL bound to the DTg BCR was evaluated. DTg B cells
were treated with CD40L alone or with CD40L in con-
junction with biotin-conjugated sHEL in the presence or
absence of SA for 16 h, and then tested as targets for Th1-
CMC. As shown in Fig. 4, SA-induced cross-linking of bi-
otinylated sHEL produced Fas resistance in DTg B cells
that were unaffected by treatment with sHEL alone (native
or biotinylated). Furthermore, the level of Fas resistance
produced by cross-linked sHEL approximated that pro-
duced by anti-IgM–induced BCR cross-linking. These
findings suggest that the sIg-triggered pathways responsible
for bringing about resistance to Th1-CMC remain intact in
tolerant B cells. However, it appears that a higher order of
BCR engagement is required for induction of Fas resis-
tance in tolerant as opposed to nontolerant B cells.
Beyond the antigen receptor, engagement of the IL-4
receptor has been shown to induce Fas resistance in non-
tolerant B cells (13). To examine the capacity of IL-4 to
mediate Fas resistance in tolerant B cells, cytotoxicity assays
were carried out after concurrent treatment of B cell targets
with CD40L plus IL-4 for 16 h. As shown in Fig. 5, the
addition of IL-4 to CD40L over a range of doses produced
Figure 3. HEL is bound by transgenic receptors in tolerant B cells. Pri-
mary B cells from STg or DTg mice were examined before and after ad-
dition of sHEL at 100 ng/ml for 1 h at 48C in the presence of 0.1% so-
dium azide. B cells were stained with biotin-conjugated anti-HEL monoclonal
antibody HyHEL9, followed by PE-conjugated SA, in the presence of 2%
rabbit serum. Stained cells were analyzed by flow cytometry; relative cell
number is shown as a function of fluorescence intensity. One of three
comparable experiments is shown.
Figure 4. Cross-linking sHEL induces Fas resistance in tolerant B cells.
Primary B cells from DTg mice were stimulated with either CD40L–CD8a
fusion protein cross-linked with CD8-specific antibody (CD40L), CD40L
plus F(ab9)2 fragments of goat anti–mouse IgM antibody at 10 mg/ml
(CD40L/aIgM), CD40L plus SA at 10 mg/ml (CD40L/SA), CD40L plus
soluble HEL at 100 ng/ml (CD40L/sHEL), CD40L plus biotin-conju-
gated sHEL at 100 ng/ml (CD40L/bio-sHEL), and CD40L plus bio-sHEL
followed by SA (CD40L/bio-HEL/SA), as indicated. B cells were then ra-
diolabeled and tested for susceptibility to Fas-dependent lysis in standard
4-h lectin-dependent 51Cr–release assays using AE7 CD41 Th1 effector
cells. Results for E/T cell ratios of 9:1 are presented. For each condition,
the mean percentage of specific lysis of triplicate assays is displayed, along
with a line indicating the SEM. One of three comparable experiments is
shown.851 Foote et al.
similar levels of resistance to Th1-CMC both in tolerant B
cells from DTg mice and nontolerant B cells from STg
mice. This is consistent with previous reports that IL-4R
signaling in tolerant B cells is unimpaired (19, 20). In nei-
ther case could IL-4–mediated Fas resistance be attributed
to a change in the level of Fas expression (compare with
Fig. 1 A). Thus, physiologic engagement of IL-4R in toler-
ant B cells produces Fas resistance, whereas BCR engage-
ment by specific antigen does not.
Discussion
Our results delineate the regulation of Fas-mediated apop-
tosis in tolerant B cells. In several respects tolerant B cells
behave like nontolerant B cells: susceptibility to Fas killing
is produced by CD40 engagement and is opposed by
higher order cross-linking of surface immunoglobulin and
by engagement of IL-4 receptors by physiological ligand.
However, tolerant B cells differed markedly from nontoler-
ant B cells in the response to BCR triggering by cognate
antigen, in that Fas-resistance is not induced in tolerant B
cells but is induced in nontolerant B cells. These results
show for the first time that specific antigen fails to elicit
Fas-resistance in tolerant B cells, but that tolerant B cells
may be protected against Fas killing by higher order BCR
engagement and by engagement of IL-4R.
Tolerant B cells can be lost through a Fas-dependent
mechanism (references 24 and 25 and our results), and Fas
deficiency is associated with substantial autoreactive anti-
body formation (22, 23), suggesting that interference with
the susceptibility of tolerant B cells to Fas-mediated apop-
tosis may play a role in autoimmunity. This work suggests
two mechanisms by which tolerant autoreactive B cells
may escape Fas-dependent deletion. One involves high or-
der cross-linking of surface immunoglobulin such as might
be produced by immune complexes or by elevated levels of
multivalent antigen. The other involves Th2-derived IL-4.
Notably, sepsis may result in conditions fostering Fas-resis-
tance in tolerant B cells in view of the association between
overwhelming microbial infection, circulating microbial
antigen, and elevated levels of cytokines (32). Considering
the observation that autoantibodies in some cases recognize
microbial antigens (33–35), it may be hypothesized that Fas
resistance in tolerant B cells could be responsible for re-
turning autoreactive B cells to the immunocompetent
pool, resulting in the production of antimicrobial antibod-
ies that cross-react with self, at the risk of initiating autoim-
munity. This would be consistent with our earlier finding
that IL-4 overexpressing transgenic mice express serological
autoreactivity (13).
Tolerant B cells were relatively restricted in the nature of
sIg cross-linking capable of inducing Fas resistance, in con-
trast to nontolerant B cells, which were more permissive.
This suggests that a threshold exists in the level of BCR
stimulation required to complete signaling for Fas resis-
tance, and that the threshold is higher for tolerant as op-
posed to nontolerant B cells. Consistent with this, we
found that B7.2 (CD86) expression, although effectively
induced in tolerant B cells by anti-IgM, was poorly stimu-
lated by sHEL, whereas both agents induced B7.2 in non-
tolerant B cells (data not shown).
It is worth noting that induction of Fas resistance by sol-
uble antigen in nontolerant, BCR transgenic B cells ex-
tends our earlier observation that Fas resistance is induced
in normal, wild-type B cells by cognate antigen that is
membrane bound (8), and provides a direct explanation for
the improved recovery of nontolerant HEL-specific B cells
after adoptive transfer with sHEL and HEL-specific T cells
(24, 25).
In sum, these results indicate that tolerant B cells are rel-
atively insulated from self-antigen–induced modulation of
the Fas death pathway, but, through the influence of IL-4
or super-threshold levels of BCR stimulation, may acquire
Fas resistance and thereby contribute to autoantibody for-
mation.
Figure 5. IL-4 induces Fas resistance in tolerant B cells. Primary B cells
from STg (black bars) or DTg (hatched bars) mice were stimulated with ei-
ther CD40L–CD8a fusion protein cross-linked with CD8-specific anti-
body (CD40L), or CD40L plus IL-4 at the doses indicated in U/ml
(CD40L1IL-4), for 16 h, as indicated. B cells were then radiolabeled and
tested for susceptibility to Fas-dependent lysis in standard 4-h lectin-
dependent 51Cr–release assays using AE7 CD41 Th1 effector cells. Re-
sults for E/T cell ratios of 3:1 are presented. For each condition, the mean
percentage of specific lysis of triplicate assays is displayed, along with a line
indicating the SEM. One of three comparable experiments is shown.
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